---
title: "Moleculin says MIRACLE trial posts 37% interim CRc rate in venetoclax-failed AML patients"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294510325.md"
description: "Moleculin Biotech reported interim data from the MIRACLE trial showing a 37% complete remission rate in venetoclax-failed AML patients. No cardiac toxicity signals were observed. Enrollment reached 74 of 90 patients, with final Part A treatment expected in September 2026 and comprehensive unblinded results anticipated between December 2026 and February 2027."
datetime: "2026-07-31T12:05:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294510325.md)
  - [en](https://longbridge.com/en/news/294510325.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294510325.md)
---

# Moleculin says MIRACLE trial posts 37% interim CRc rate in venetoclax-failed AML patients

-   Moleculin Biotech reported updated interim data from Part A of its pivotal MIRACLE trial in relapsed or refractory acute myeloid leukemia. \* Results have been disclosed now in a blinded analysis; comprehensive unblinded Part A results are expected in the December 2026 to February 2027 window. \* Patients who previously failed venetoclax showed remission outcomes broadly consistent with the overall study population. \* The company continued to report no signal of cardiac toxicity, supporting its differentiation from standard anthracyclines. \* Enrollment reached 74 of 90 patients; the final Part A treatment is expected in September 2026, a key step toward advancing the program. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-025167), on July 31, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [MBRX.US](https://longbridge.com/en/quote/MBRX.US.md)

## Related News & Research

- [Moleculin Biotech Highlights Promising MIRACLE Trial Remission Data](https://longbridge.com/en/news/294515449.md)
- [Moleculin reports interim results from MIRACLE trial in r/r AML patients](https://longbridge.com/en/news/294705884.md)
- [Moleculin Biotech prices offering with warrants for 37,130,001 shares at $0.75 exercise price](https://longbridge.com/en/news/294525518.md)
- [Cullinan to launch registrational Phase 2 CLN-049 trial in relapsed/refractory AML in Q3 2026](https://longbridge.com/en/news/294054305.md)
- [FDA clears additional patient enrollment for Xvivo Heart Assist Transport CAP study](https://longbridge.com/en/news/294653949.md)